Current Pharmacogenomics and Personalized Medicine (CPPM) is an international peer reviewed biomedical journal that publishes expert reviews and original research on all aspects of pharmacogenomics and personalized medicine under a single cover.

The CPPM strives to move beyond the traditional compartmentalization of biomarker technology platforms and their application contexts in biomedicine through an integrated perspective on personalized health interventions.

We are interested in personalization of health interventions ranging from drugs and medical devices to nutrition and more generally, variability in host-environment interactions and its mechanistic determinants.

The journal gives priority to insightful, lucid, authoritative reviews and feature commentaries that present an original and balanced synthesis of the literature on personalized medicine and enabling ‘-omics’ technologies including, but not limited to, genomics, transcriptomics, proteomics and metabolomics. All application contexts from preclinical and translational research to routine clinical medicine are covered, including drug target discovery, biomarker guided clinical drug development, bioinformatics, bioethics, health technology assessment, novel diagnostics, pharmacoeconomics, risk assessment and systems biology, science and society interactions, as long as the authors contextualize and integrate these subjects specifically for personalized medicine.

Original research articles with a strong applied or translational focus on personalized medicine are also considered.

All submissions undergo initial screening by the editors. Only those articles that may potentially pass the rigorous standards of the peer review process are sent out for critical appraisal by expert referees invited from the international editorial board and the broader scientific community.

Celebrating its 6th year anniversary, the journal offers an integrated multidisciplinary international forum and has become an indispensable reading for academic researchers, clinicians and health professionals, policy makers as well as pharmaceutical industry, healthcare management and government stakeholders who share an interest in pharmacogenomics and personalized medicine.